Clinical and MRI substrates of Symbol Digit Modalities Test impairment in multiple sclerosis patients with an adult- and late-onset
Substrates contributing to SDMT impairment differ between these two distinct cohorts, being primarily driven by network dysfunction in AOMS and neurodegenerative processes in LOMS.
Authors
- Elisabeth Solana (ORCID: https://orcid.org/0000-0001-7973-2439)
- Matthias Weigel (ORCID: https://orcid.org/0000-0002-4910-1414)
- Antonia Wenger
- Antonio Gallo (ORCID: https://orcid.org/0000-0002-4045-3237)
- Alessandro Cagol
- Cristina Granziera
- Paolo Preziosa
- Massimo Filippi
- Mario A Ocampo-Pineda
- Christian Enzinger
- Pasquale Calabrese
- Elisabetta Pagani
- Maria A Rocca
- Ludwig Kappos
- Alessandro Meani
- Menno M Schoonheim
Institutions
- Vita-Salute San Raffaele University (IT)
- University of Basel (CH)
- Johannes Gutenberg University Mainz (DE)
- University of Campania "Luigi Vanvitelli" (IT)
- Medical University of Graz (AT)
- University Hospital of Basel (CH)
- Hospital Base (CL)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- Amsterdam Neuroscience (NL)
- Amsterdam University Medical Centers (NL)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
- Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele (IT)
- Universitat de Barcelona (ES)
- Vrije Universiteit Amsterdam (NL)
Publication Details
- Journal
- Multiple Sclerosis Journal
- Published
- 2026-02-23
- DOI
- https://doi.org/10.1177/13524585261417265
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Sanofi
- Biogen
- Teva Pharmaceutical Industries
- Alexion Pharmaceuticals
- Celgene
- F. Hoffmann-La Roche
- Fondazione Italiana Sclerosi Multipla
- Fondation pour l'Aide à la Recherche sur la Sclérose en Plaques
- European Committee for Treatment and Research in Multiple Sclerosis
- TG Therapeutics
- Atara Biotherapeutics
- Horizon Therapeutics
- Multiple Sclerosis Society of Canada
- Multiple Sclerosis Society
- Bayer HealthCare
- National Research Foundation
- ZonMw
- Ministero della Salute
- Eisai
- Novo Nordisk
- Shionogi
- Schweizerische Multiple Sklerose Gesellschaft
- H. Lundbeck A/S
- Innosuisse - Schweizerische Agentur für Innovationsförderung
- Ipsen
- Neuraxpharm
- MedDay Pharmaceuticals
- Amsterdam Neuroscience
- Genentech
- EMD Serono
- Eurostars